Teza Capital Management LLC purchased a new position in Haemonetics Co. (NYSE:HAE – Get Rating) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 2,850 shares of the medical instruments supplier’s stock, valued at approximately $211,000.
A number of other hedge funds also recently modified their holdings of HAE. Wipfli Financial Advisors LLC acquired a new stake in Haemonetics in the third quarter valued at about $25,000. Eagle Bay Advisors LLC boosted its stake in Haemonetics by 155.1% in the second quarter. Eagle Bay Advisors LLC now owns 653 shares of the medical instruments supplier’s stock valued at $43,000 after buying an additional 397 shares in the last quarter. FinTrust Capital Advisors LLC acquired a new stake in Haemonetics in the third quarter valued at about $60,000. Altshuler Shaham Ltd acquired a new stake in Haemonetics in the third quarter valued at about $59,000. Finally, SeaCrest Wealth Management LLC acquired a new stake in Haemonetics in the second quarter valued at about $65,000.
Wall Street Analyst Weigh In
A number of analysts have recently commented on HAE shares. Citigroup lifted their price target on Haemonetics from $92.00 to $95.00 and gave the company a “neutral” rating in a research note on Wednesday, February 8th. Barrington Research lifted their price target on Haemonetics from $94.00 to $103.00 and gave the company an “outperform” rating in a research note on Wednesday, February 8th. Morgan Stanley lifted their price target on Haemonetics from $84.00 to $88.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 8th. Finally, Mizuho lifted their price target on Haemonetics from $110.00 to $115.00 and gave the company a “buy” rating in a research note on Wednesday, February 8th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $101.00.
Haemonetics Price Performance
Haemonetics (NYSE:HAE – Get Rating) last posted its quarterly earnings data on Tuesday, February 7th. The medical instruments supplier reported $0.85 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.06. The company had revenue of $305.30 million for the quarter, compared to analyst estimates of $300.47 million. Haemonetics had a return on equity of 19.84% and a net margin of 8.48%. The firm’s quarterly revenue was up 17.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.84 earnings per share. As a group, research analysts expect that Haemonetics Co. will post 2.94 EPS for the current year.
Insiders Place Their Bets
In other Haemonetics news, EVP Josep Llorens sold 2,391 shares of Haemonetics stock in a transaction that occurred on Monday, January 23rd. The stock was sold at an average price of $90.00, for a total value of $215,190.00. Following the completion of the sale, the executive vice president now directly owns 17,234 shares in the company, valued at $1,551,060. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 1.65% of the stock is currently owned by corporate insiders.
Haemonetics Profile
Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems.
Featured Stories
- Get a free copy of the StockNews.com research report on Haemonetics (HAE)
- First Republic: First Rate Risk or Time To Buy?
- These Hedge Funds Are Getting Crushed By SVB
- Buy The Dip In The Charles Schwab Corporation
- ZIM Integrated Shipping Services: Up 15% But Don’t Chase It
- FedEx Is A Buy Going Into Earnings
Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE – Get Rating).
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.
